A new report by visiongain predicts that the overall world antithrombotic and anticoagulant drug market will reach 24.4 billion dollars in 2015. That forecast appears in Antithrombotic/Anticoagulant Drugs: World Market 2012-2022, published in January 2012. Visiongain is a business information provider based in London, UK.
The new study assesses drugs to treat abnormal blood clotting in human beings. It predicts that the industry and market for blood thinners will soon recover from the patent expiries of two leading drugs, Plavix and Lovenox. The overall world antithrombotic treatments market will show a gradual increase in sales revenues to 2022. Supporting that expansion will be increasing disease incidence, prevalence and diagnosis, especially in the developing markets of China and India.
Kritika Chaudhari, a pharmaceutical industry analyst at visiongain, said: “The launch of new oral anticoagulants with better safety and efficacy profiles, easier dosing regimens and compliance- facilitating delivery methods will be welcome in the market. These drugs are likely to replace some older treatments. There are unmet needs in this medical area. Pharmaceutical companies will further explore this field, making progress this decade. Blood thinners will play important roles in medicine, helping to prevent and treat cardiovascular disorders.”
This study forecasts revenues of ten leading drugs in the antithrombotic agents market, including Plavix, Lovenox, Pletal, Fragmin, Asasantin, Arixtra and Aspirin Cardio. The report also predicts revenues of newly launched drugs: Brilinta, Xarelto, Pradaxa and Effient. Analyses and discussions cover activities of Eli Lilly, Boehringer Ingelheim, AstraZeneca, J&J, Bayer, Sanofi, Merck, Eisai, Daiichi Sankyo and other pharmaceutical companies.
In addition to forecasting the overall world market and leading national markets, the work predicts revenue trends for submarkets. It forecasts sales of platelet aggregation inhibitors, heparins, fibrinolytics, vitamin K antagonists, direct thrombin inhibitors and direct factor Xa inhibitors. The report provides revenue values to 2022 at world market, therapeutic class, product and national levels.
The antithrombotic drug market is expanding. Safer and more efficacious drugs are in demand. Also in demand are antidotes to stop excessive bleeding after treatment. This new report discusses market drivers, restraints and opportunities of revenue growth for blood-thinning drugs. It adds to visiongain’s wide range of analytical research on industries and markets in healthcare, including the treatment of cardiovascular disorders.
For sample pages and further information concerning the Visiongain report Antithrombotic/Anticoagulant Drugs: World Market 2012-2022 please visit http://www.visiongain.com/Report/743/Antithrombotic-Anticoagulant-Drugs-World-Market-2012-2022
For an executive summary of this report please email:
Sara Peerun at sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100
About visiongain
Visiongain is one of the fastest growing and most innovative independent business intelligence companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters and management reports focusing on the Energy, Telecoms, Pharmaceuticals, Defence, Aviation and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.